CL
CLGN.US Collplant Biotechnologies Ltd
- Market cap
- USD 14.3M
- P/E
- -
- P/B
- 4.85x
- ROE
- -395.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CLGN.US undervalued?
Graham numberThe Graham number of Collplant Biotechnologies Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Collplant Biotechnologies Ltd fundamental analysis
No fundamental analysis for Collplant Biotechnologies Ltd yet.
Collplant Biotechnologies Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a c…
Full company profileCollplant Biotechnologies Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Collplant Biotechnologies Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 75.9K | 480K | 4.79M | 2.32M | 6.14M | 15.6M | 299K | 11.0M | 515K | 2.37M | 362K |
| Gross Profit | -149K | 158K | 3.11M | 439K | 2.68M | 13.6M | -1.18M | 7.87M | -2.15M | 624K | -1.79M |
| Operating Income | -7.16M | -5.97M | -4.07M | -7.63M | -5.60M | 65.0K | -17.1M | -7.51M | -17.3M | -11.5M | -11.5M |
| EBITDA | -7.03M | -5.47M | -5.88M | -10.6M | -5.08M | 1.05M | -15.8M | -5.91M | -15.6M | -10.6M | -10.6M |
| Net Income | -7.27M | -5.80M | -6.25M | -11.2M | -5.77M | 237K | -16.9M | -7.02M | -16.6M | -11.5M | -11.6M |
| EPS | -36 | -22 | -14 | -22 | -8.38 | 0.20 | -15 | -6.16 | -15 | -9.41 | -8.07 |
| Balance Sheet | |||||||||||
| Total Assets | 3.75M | 8.07M | 9.05M | 10.8M | 10.8M | 51.2M | 37.8M | 34.1M | 18.7M | 10.8M | 7.20M |
| Total Liabilities | 2.41M | 5.46M | 4.29M | 6.66M | 6.36M | 6.10M | 5.49M | 5.79M | 5.25M | 4.70M | 4.25M |
| Shareholders' Equity | 1.34M | 2.61M | 4.76M | 4.09M | 4.48M | 45.1M | 32.3M | 28.3M | 13.5M | 6.08M | 2.95M |
| Cash & Short-term Investments | 987K | 5.13M | 5.33M | 3.79M | 3.33M | 43.3M | 29.7M | 26.7M | 11.9M | 5.95M | 2.95M |
| Total Debt | - | 3.64M | 44.6K | 3.62M | 3.39M | 3.61M | 2.91M | 3.16M | 3.08M | 2.85M | 2.66M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.02M | -4.97M | -1.22M | -5.70M | -4.45M | 2.50M | -13.7M | -2.76M | -14.1M | -9.42M | -11.0M |
| Capital Expenditure | 128K | 127K | 832K | 1.49M | 437K | 1.43M | 1.27M | 954K | 483K | 28.0K | 154K |
| Free Cash Flow | -5.15M | -5.09M | -2.05M | -7.19M | -4.89M | 1.07M | -15.0M | -3.72M | -14.6M | -9.45M | -11.2M |
| Ratios | |||||||||||
| ROE | -541.7% | -222.1% | -131.3% | -273.1% | -129.0% | 0.5% | -52.4% | -24.8% | -123.3% | -188.9% | -395.4% |
| ROA | -193.7% | -71.9% | -69.1% | -103.8% | -53.3% | 0.5% | -44.8% | -20.6% | -88.8% | -106.5% | -161.8% |
| Net Profit Margin | -9,571.9% | -1,209.6% | -130.5% | -481.6% | -94.1% | 1.5% | -5,660.5% | -64.0% | -3,225.0% | -484.6% | -3,217.1% |
| Debt to Equity | - | 1.39x | 0.01x | 0.89x | 0.76x | 0.08x | 0.09x | 0.11x | 0.23x | 0.47x | 0.90x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Collplant Biotechnologies Ltd dividends
Collplant Biotechnologies Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Sep 4, 2026.
Who owns Collplant Biotechnologies Ltd
- Insiders 20.85%
- Institutions 7.37%
- Public & others 71.79%
- Shares outstanding 3.08M
- Free float 865K
Top funds holding CLGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 5.93K | 0.05% | 0.00% | Jul 2025 |
Top institutions holding CLGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Parallel Advisors, LLC | 71.00 | 0.00% | 0.00% | Jun 2026 |
Collplant Biotechnologies Ltd company profile
- Company name
- Collplant Biotechnologies Ltd
- Ticker
- CLGN.US
- ISIN
- IL0004960188
- Exchange
- USA Stocks
- Listed since
- Jan 30, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 39
- Fiscal year end
- December
- Address
- Weizmann Science Park, Rehovot, Israel, 7670104
- Phone
- 972 73 232 5600
- Website
- collplant.com
About Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Collplant Biotechnologies Ltd management
4- Mr. Oren FahimipoorVice President of Operations · born 1982
- Dr. Oded ShoseyovFounder & Chief Scientist · born 1956
- Ms. Bar AbelisVice President of Legal
- Ms. Hadas Dreiher HorowitzVice President of Human Resources · born 1977